An Evaluation of Butoconazole Nitrate 2% Site Release® Vaginal Cream (Gynazole-1®) Compared to Fluconazole 150 mg Tablets (Diflucan®) in the Time to Relief of Symptoms in Patients With Vulvovaginal Candidiasis
Background. It is estimated that as many as 13 million cases of vulvovaginal infection occur in the United States annually, the majority of which are the result of Candida albicans infection. The symptoms of vulvovaginal infections are often painful and distressing to the patient. The objective of t...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hindawi Limited
2005-01-01
|
| Series: | Infectious Diseases in Obstetrics and Gynecology |
| Online Access: | http://dx.doi.org/10.1080/10647440500240615 |
| Summary: | Background. It is estimated that as many as 13 million cases of vulvovaginal infection occur in the United States annually, the majority of which are the result of Candida albicans infection. The symptoms of vulvovaginal infections are often painful and distressing to the patient. The objective of this study was to compare the time to symptomatic relief of vulvovaginal candidiasis (VVC) with butoconazole nitrate 2% Site Release® vaginal cream (Gynazole-1®) and oral fluconazole 150 mg tablets (Diflucan®). |
|---|---|
| ISSN: | 1064-7449 1098-0997 |